Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
about
Radiation therapy for hepatobiliary malignancies.Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancerQuality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer.The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.Hypofractionated radiotherapy for localized prostate cancer.Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?Progress and controversies: Radiation therapy for prostate cancer.Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: a Critical Review.Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes.Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?Travel distance and stereotactic body radiotherapy for localized prostate cancer.Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.A feasibility study of a hybrid breast-immobilization system for early breast cancer in proton beam therapy.Current modulated volume-of-interest imaging for kilovoltage intrafaction monitoring of the prostate.Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques.Using daily diagnostic quality images to validate planning margins for prostate interfractional variationsUtilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.
P2860
Q33593244-0ACF1531-8BC5-47CB-9850-BB937FFC38B8Q33659901-3C0BA92A-DC69-4B00-A541-2478C171B092Q34413524-66DADA1B-ED65-4D37-AC34-E268930FC285Q35649108-417678A3-55AB-4507-BD9A-89986E70632AQ36969645-29C28F2D-2EE5-41F6-A947-E6127A11E959Q37195789-A0C95A44-1667-4A47-9B78-459A36146EA1Q37547386-9E2608CD-328F-43D3-A536-9C6C31A17A3AQ37578562-0621FBD9-D2A8-4175-B1D7-C93460375144Q38252429-5CFCB837-80BC-4AF5-921F-5D1E44786F2DQ38437266-3EDD7AD9-F4E6-423E-B199-6C304907F780Q38863898-7ACADF76-3A10-4BDD-B934-BB3D936741F5Q39007067-75F152F4-B1A2-47C9-A5A7-0130ECF03171Q39078034-F8D18974-ECEB-4A60-B7C3-633D001B0354Q39249966-4DCD3B63-6CF3-4317-9592-B957BEE72117Q39736576-4A0013A8-E682-4271-B2F9-ADCE16C428F7Q39772182-31B8D873-8263-4F31-B132-73A17FF76518Q40289101-B86E0ACF-6BB7-4492-A3ED-11D6CE4D26EBQ40965160-798AD1E5-C969-4F72-8800-6209351B1020Q41633448-8152F18E-4ADC-41F3-B8D8-B2D12E5E56F5Q42364887-91A867F2-4EEC-48E3-8441-7B7D0302DEB6Q42857993-DF82BD1C-248A-4A9E-97A9-6CE03D705DBBQ45989369-539DCE8E-0B39-486F-BAF7-A598704A2C8BQ46084626-2A7890A7-6BFC-4030-9766-25BAD637E303Q47185878-3E545011-5EC1-4F0B-A184-1567D40D878CQ47855930-E8D456F1-E46D-4E6F-8BA2-0F2753CFF903Q51025470-C983B174-4174-4DC3-B7C0-C73C0E33B80FQ52450428-B6AABE14-F4C0-4F1F-BF33-7F3E908D98B1Q52983030-3737F67D-17A6-4EC9-B627-80F7DE5A1E4CQ53292172-2EB1857B-1235-4C62-B9E0-9D2F43D5F9DBQ54358254-C05D2D29-DC62-4912-B180-11E6C3ED3CEC
P2860
Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@en
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@nl
type
label
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@en
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@nl
prefLabel
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@en
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@nl
P2093
P2860
P356
P1476
Stereotactic body radiation th ...... ancer: comparison of toxicity.
@en
P2093
Arnold L Potosky
Cary P Gross
Jeph Herrin
Laura D Cramer
Pamela R Soulos
P2860
P304
P356
10.1200/JCO.2013.53.8652
P407
P50
P577
2014-03-10T00:00:00Z